These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 34563169)
1. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure. Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169 [TBL] [Abstract][Full Text] [Related]
2. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597 [TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Apolo AB; Nadal R; Tomita Y; Davarpanah NN; Cordes LM; Steinberg SM; Cao L; Parnes HL; Costello R; Merino MJ; Folio LR; Lindenberg L; Raffeld M; Lin J; Lee MJ; Lee S; Alarcon SV; Yuno A; Dawson NA; Allette K; Roy A; De Silva D; Lee MM; Sissung TM; Figg WD; Agarwal PK; Wright JJ; Ning YM; Gulley JL; Dahut WL; Bottaro DP; Trepel JB Lancet Oncol; 2020 Aug; 21(8):1099-1109. PubMed ID: 32645282 [TBL] [Abstract][Full Text] [Related]
4. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775 [TBL] [Abstract][Full Text] [Related]
5. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373 [TBL] [Abstract][Full Text] [Related]
6. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359 [TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. Desai A; Small EJ Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937 [TBL] [Abstract][Full Text] [Related]
8. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946 [TBL] [Abstract][Full Text] [Related]
11. [Cabozantinib: Mechanism of action, efficacy and indications]. Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875 [TBL] [Abstract][Full Text] [Related]
12. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Grüllich C Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794 [TBL] [Abstract][Full Text] [Related]
13. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062 [TBL] [Abstract][Full Text] [Related]